HLI

Analyst Note: Houlihan Lokey, Inc. (HLI)

Date: 2026-06-13 Current Price: $140.77

1. Structural Readiness

State: Context-Only Conservative Entry: — Breakout Level: — Extension: — ATR Current: 3.1% (Productive)

Setup Classification: FORMING

2. Thesis Layer

Thesis Status: Tactical / Setup-Led There is no named secular thesis attached to HLI as of this date. The investment case is not driven by a specific macro narrative (e.g., "Private Credit Crisis Play" or "AI Infrastructure Boom") but is strictly setup-led. The conviction must be derived entirely from the quality of the technical structure (the forming coil) and the underlying business fundamentals. We are judging this name on its ability to execute its business model and the structural readiness of the chart, rather than on a pre-existing macro tailwind.

3. The Business

Houlihan Lokey, Inc. is a global investment banking firm operating in the Financial Services sector, specifically within Investment Banking & Brokerage. The company operates on an advisory model, generating revenue primarily through transaction fees and retainers rather than proprietary trading or balance sheet lending.

Core Segments & Performance (as of FY2026):

• Corporate Finance (CF): Provides M&A advisory, capital markets offerings, and strategic guidance.
• *Evidence:* In the nine months ended December 31, 2025, CF revenues reached $1.31 billion, an 18% increase year-over-year (E12).
• *Evidence:* For the full fiscal year 2026, CF produced record revenues (E5).
• *Evidence:* The firm closed 171 transactions in the most recent quarter, up from 147 in the prior year period (E6).
• Financial Restructuring (FR): Advises on bankruptcy proceedings, distressed M&A, and capital markets activities.
• *Evidence:* FR had one of the strongest years on record in fiscal 2026 (E5).
• *Evidence:* The firm serves as a countercyclical hedge, with restructuring opportunities often rising when M&A demand falls (E21).
• Financial Valuation and Advisory (FVA): Specializes in appraisals and dispute resolution.
• *Evidence:* FVA also produced record revenues for the year (E5).

Financial Health & Guidance:

• Revenue: The company ended fiscal year 2026 with record revenue of $2.6 billion, up 10% year-over-year (E1).
• Profitability: Adjusted EPS was $7.56, up 20% year-over-year (E1).
• Efficiency: The Compensation Ratio was 64.3% for the nine months ended December 31, 2025, compared to 63.5% the prior year, indicating stable cost management despite revenue growth (E15).
• Pipeline: Management reported a record level of backlog and pipeline (E2) and a record number of corporate acquisition opportunities (E7).
• Forward Outlook: Management expects fiscal 2027 performance to be elevated, citing "widening credit spreads," "dislocation in private credit," and "energy volatility" as tailwinds driving activity (E3, E4).

4. Archetype and Conviction

Archetype: Quality Compounder HLI fits the Quality Compounder archetype. The evidence points to a firm with a durable competitive advantage (market share in sell-side M&A for sub-$1B deals), a diversified revenue stream (CF + FR + FVA), and a history of consistent earnings growth.

• Margin Inflector: The 20% EPS growth outpacing the 10% revenue growth suggests operating leverage and effective cost control (E1).
• Valuation Context: The financial spine indicates a forward consensus EPS of $7.70 for FY1 and $8.15 for FY2 (E34). At a current price of $140.77, the stock trades at approximately 18.3x forward FY1 EPS.
• Conviction Stack:
• *Thesis Strength:* Low (Tactical only).
• *Evidence Quality:* High. The earnings transcript and filings provide robust, quantitative confirmation of record performance and improved guidance.
• *Structural Quality:* Moderate. The setup is "Forming," meaning the structural quality is present but unconfirmed by a breakout.
• *Rerating Potential:* Moderate. The market is pricing in the record results; a rerating would require the "Forming" coil to resolve into a "Confirmed" breakout, signaling institutional accumulation.

5. Invalidations, Strengths, and Gaps

What Would Strengthen the Case:

• Guidance Raise: Management explicitly raising the FY2027 revenue or EPS guidance beyond the current "elevated" expectations.
• Deal Volume Surge: Public announcements of multiple large-scale transactions in the CF or FR segments exceeding the current record pace.

What Would Invalidate the Case:

• Fundamental Deterioration: A significant miss in FY2027 guidance or a contraction in the "record backlog" reported in May 2026.
• Margin Compression: A sharp increase in the Compensation Ratio beyond the 64.3% level, indicating an inability to convert revenue growth into profit.

Evidence Gaps:

• Institutional Flow Data: No evidence is available regarding recent insider trading or institutional accumulation/distribution patterns.
• Macro Specifics: While management cites "widening credit spreads," specific data on the magnitude of these spreads or the exact volume of private credit dislocations is not quantified in the provided evidence.

PRIVATE ANALYST CALL

Judgment: Buy Confidence: medium Key evidence: Record $2.6B FY2026 revenue with 10% growth; Adjusted EPS up 20% to $7.56; Management raised FY2027 expectations citing record backlog and specific tailwinds in private credit and energy. Key risks: Technical setup remains "Forming" with no breakout fired yet; Compensation ratio ticked up to 64.3% indicating potential margin pressure; Tactical setup lacks a named secular thesis to drive momentum. Sizing hint: Position size should reflect the "Forming" state—smaller than a confirmed breakout, sized for the probability of a successful resolution rather than immediate certainty. Expected horizon: 3 to 6 months for the structural setup to resolve into a confirmed breakout or invalidation.